Literature DB >> 593868

[Immobilisation hypercalcaemia (author's transl)].

P Minaire, P Meunier, E Berard, R Girard, J Bourret.   

Abstract

Hypercalcaemia would seem to be rare during immobilisation, whilst osteoporosis and hypercalciuria are constant. In fact, it often goes unnoticed. The case presented here confirms its predominance in the adolescent male. The reason for immobilisation seems to be irrelevant. The clinical symptoms are very variable: polydipsia, nausea, headache, apathy, anorexia. Blood calcium levels are raised, up to 14 mg%. This hypercalcaemia is due to very marked bone loss in adolescents, secondary to hyper-resorption and a temporary stoppage in osseous formation. The differential diagnosis from primary hyperparathyroidism is sometimes difficult but is aided by laboratory and histological findings. The essential is to consider the possibility of immobilisation hypercalcaemia in the presence of any suggestive symptoms in an immobilised adolescent. Treatment includes a return to weight bearing, adequate water intake and the administration of phosphorus, calcitonin, furosemide, and corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 593868

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  5 in total

1.  Progressive hypercalcemia during continuous arterio-venous ultrafiltration (SCUF).

Authors:  H E van der Wiel; H J Voerman; L G Thijs
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 2.  Immobilization osteoporosis: a review.

Authors:  P Minaire
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

3.  The effect of short-term calcitonin administration on biochemical bone markers in patients with acute immobilization following hip fracture.

Authors:  N Tsakalakos; B Magiasis; M Tsekoura; G Lyritis
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

4.  Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.

Authors:  N Varache; M Audran; P Clochon; A Lortholary; G Bouachour; P Alquier; M F Basle
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

5.  Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients.

Authors:  P Minaire; E Berard; P J Meunier; C Edouard; G Goedert; G Pilonchery
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.